In an unusual pivot, Swiss biotech Basilea looks to ditch cancer pipeline in favor of — anti-infectives?
Oncology has been the single largest driver of revenues across biopharma for years now, and you’re more likely than ever to see a company ditch all other plans to chase that white rabbit. But a Swiss biotech is betting its future on a perpendicular path, opting to ditch its oncology assets instead.
Switzerland-based Basilea will look to offload its oncology pipeline in part or in full as part of a reorganization of its R&D pipeline around anti-infectives, including its two approved drugs in that space, the biotech said Tuesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.